NASDAQ:VIR Vir Biotechnology (VIR) Stock Price, News & Analysis → Democrats’ “break glass for emergency” candidate for 2024 (From The Freeport Society) (Ad) Free VIR Stock Alerts $10.36 -0.12 (-1.15%) (As of 06/13/2024 ET) Add Compare Share Share Today's Range$10.08▼$10.4450-Day Range$7.63▼$12.6652-Week Range$7.61▼$26.74Volume1.21 million shsAverage Volume1.06 million shsMarket Capitalization$1.41 billionP/E RatioN/ADividend YieldN/APrice Target$34.14 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Vir Biotechnology alerts: Email Address Vir Biotechnology MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.57 Rating ScoreUpside/Downside229.6% Upside$34.14 Price TargetShort InterestBearish6.78% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.71Based on 10 Articles This WeekInsider TradingSelling Shares$820,997 Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($3.57) to ($3.82) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.30 out of 5 starsMedical Sector513th out of 917 stocksBiological Products, Except Diagnostic Industry74th out of 153 stocks 3.3 Analyst's Opinion Consensus RatingVir Biotechnology has received a consensus rating of Moderate Buy. The company's average rating score is 2.57, and is based on 4 buy ratings, 3 hold ratings, and no sell ratings.Amount of Analyst CoverageVir Biotechnology has only been the subject of 4 research reports in the past 90 days.Read more about Vir Biotechnology's stock forecast and price target. Previous Next 2.0 Short Interest Percentage of Shares Shorted6.78% of the float of Vir Biotechnology has been sold short.Short Interest Ratio / Days to CoverVir Biotechnology has a short interest ratio ("days to cover") of 6.1.Change versus previous monthShort interest in Vir Biotechnology has recently decreased by 3.06%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldVir Biotechnology does not currently pay a dividend.Dividend GrowthVir Biotechnology does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for VIR. Previous Next 3.2 News and Social Media Coverage News SentimentVir Biotechnology has a news sentiment score of 0.71. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.87 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 10 news articles for Vir Biotechnology this week, compared to 4 articles on an average week.Search Interest11 people have searched for VIR on MarketBeat in the last 30 days. This is an increase of 57% compared to the previous 30 days.MarketBeat Follows2 people have added Vir Biotechnology to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Vir Biotechnology insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $820,997.00 in company stock.Percentage Held by Insiders15.60% of the stock of Vir Biotechnology is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions65.32% of the stock of Vir Biotechnology is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Vir Biotechnology's insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Vir Biotechnology are expected to decrease in the coming year, from ($3.57) to ($3.82) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Vir Biotechnology is -2.58, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Vir Biotechnology is -2.58, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioVir Biotechnology has a P/B Ratio of 0.88. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Vir Biotechnology's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Paradigm PressMan who Predicted Trump 2016 Win: “Prepare for Election Meltdown”Former advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… A predicted Trump would win. You won’t believe what he’s predicting now.Click here to see it because it’s a SHOCKER… About Vir Biotechnology Stock (NASDAQ:VIR)Vir Biotechnology, Inc., a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It offers tobevibart + elebsiran for the treatment of chronic hepatitis delta; elebsiran + PEG-IFN-a, tobevibart ± elebsiran ± PEG-IFN-a, and elebsiran+ TLR8+PD-1 for the treatment of chronic hepatitis B; VIR-1388 and Cure mAb combination for the treatment of human immunodeficiency virus; VIR-8190 for the treatment of respiratory syncytial virus / human metapneumovirus; VIR-2981 for the treatment of influenza; VIR-1949 for the treatment of pre-cancerous HPV lesions; and VIR07229 and Sotrovimab for the treatment of COVID-19 infection under the Xevudy brand. The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with MedImmune; collaboration with WuXi Biologics and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals SA. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. for the manufacture of SARS-COV-2 antibodies. The company was incorporated in 2016 and is headquartered in San Francisco, California.Read More VIR Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart VIR Stock News HeadlinesJune 13 at 9:17 AM | insidertrades.comVir Biotechnology, Inc. (NASDAQ:VIR) Director Saira Ramasastry Sells 4,000 SharesJune 13 at 9:18 AM | americanbankingnews.comVir Biotechnology, Inc. (NASDAQ:VIR) Director Saira Ramasastry Sells 4,000 Shares of StockJune 9, 2024 | americanbankingnews.comVir Biotechnology (NASDAQ:VIR) Trading Down 8%June 8, 2024 | americanbankingnews.comMorgan Stanley Raises Vir Biotechnology (NASDAQ:VIR) Price Target to $15.00June 7, 2024 | americanbankingnews.comHC Wainwright Reiterates "Buy" Rating for Vir Biotechnology (NASDAQ:VIR)June 6, 2024 | americanbankingnews.comVir Biotechnology (NASDAQ:VIR) Price Target Raised to $19.00June 5, 2024 | businesswire.comTobevibart Monotherapy and Combination Therapy with Elebsiran Achieved High Virologic Response and ALT Normalization in People Living with the Hepatitis Delta Virus After 12 and 24 Weeks of TreatmentMay 29, 2024 | finance.yahoo.comVir Biotechnology to Participate in the Goldman Sachs 45th Annual Global Healthcare ConferenceMay 29, 2024 | businesswire.comVir Biotechnology to Participate in the Goldman Sachs 45th Annual Global Healthcare ConferenceMay 29, 2024 | msn.comResearchers discover vaccine originally created for HIV may also combat cancerMay 29, 2024 | markets.businessinsider.comVir Biotechnology Appoints Mark Eisner As EVP And Chief Medical OfficerMay 24, 2024 | markets.businessinsider.comBuy Rating Affirmed for Vir Biotechnology on Promising CHD and CHB Program ProspectsMay 24, 2024 | markets.businessinsider.comEvaluating Vir Biotechnology: Insights From 5 Financial AnalystsMay 24, 2024 | markets.businessinsider.comBuy Rating Affirmed for Vir Biotechnology on Promising HDV Program and Anticipated Trial ResultsMay 23, 2024 | finance.yahoo.comVir Biotechnology to Host 2024 Annual Meeting of StockholdersMay 23, 2024 | businesswire.comVir Biotechnology to Host 2024 Annual Meeting of StockholdersMay 22, 2024 | finance.yahoo.comMultiple Abstracts Highlighting Vir Biotechnology’s Latest Hepatitis Delta & B Data Accepted for Presentation at the EASL Congress 2024May 21, 2024 | businesswire.comVir Biotechnology Announces SOLSTICE Data to be Featured as an Oral Presentation at the European Association for the Study of the Liver (EASL) Congress 2024May 13, 2024 | prnewswire.comBrii Biosciences Announces Two Breakthrough Therapy Designations for BRII-877 and BRII-835 Building on Extensive Clinical Evidence from Multiple Phase 2 StudiesMay 8, 2024 | finance.yahoo.comAnalysts Just Shipped A Stunning Upgrade To Their Vir Biotechnology, Inc. (NASDAQ:VIR) EstimatesMay 7, 2024 | markets.businessinsider.comBuy Rating Affirmed: Anticipated Breakthroughs in Vir Biotechnology’s Clinical PipelineMay 7, 2024 | markets.businessinsider.comDeep Dive Into Vir Biotechnology Stock: Analyst Perspectives (6 Ratings)May 4, 2024 | markets.businessinsider.comBuy Rating Affirmed for Vir Biotechnology Amid Promising HDV and HBV Treatment MilestonesMay 3, 2024 | markets.businessinsider.comHold Rating on Vir Biotechnology Amid Financial Concerns and Clinical Trial UncertaintyMay 3, 2024 | finance.yahoo.comVir Biotechnology, Inc. (NASDAQ:VIR) Q1 2024 Earnings Call TranscriptSee More Headlines Receive VIR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Vir Biotechnology and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/02/2024Today6/13/2024Next Earnings (Estimated)8/01/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:VIR CUSIPN/A CIK1706431 Webwww.vir.bio Phone415-906-4324FaxN/AEmployees587Year FoundedN/APrice Target and Rating Average Stock Price Target$34.14 High Stock Price Target$110.00 Low Stock Price Target$12.00 Potential Upside/Downside+229.6%Consensus RatingModerate Buy Rating Score (0-4)2.57 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)($4.01) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-615,060,000.00 Net Margins-677.69% Pretax Margin-690.97% Return on Equity-32.58% Return on Assets-26.97% Debt Debt-to-Equity RatioN/A Current Ratio12.90 Quick Ratio12.90 Sales & Book Value Annual Sales$86.18 million Price / Sales16.36 Cash FlowN/A Price / Cash FlowN/A Book Value$11.82 per share Price / Book0.88Miscellaneous Outstanding Shares136,060,000Free Float114,834,000Market Cap$1.41 billion OptionableOptionable Beta0.50 10 Best Stocks to Own in 2024Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio. Get This Free Report Key ExecutivesDr. Marianne De Backer M.B.A. (Age 55)M.Sc., Ph.D., CEO & Director Comp: $4.47MMr. Sung H. Lee (Age 54)Executive VP & CFO Comp: $968.45kDr. Ann M. Hanly Ph.D. (Age 54)Executive VP & Chief Technology Officer Comp: $896.07kDr. Jeff Calcagno M.D. (Age 63)Executive VP & Chief Business Officer Comp: $860.49kDr. Klaus Frueh Ph.D. (Age 64)Co-Founder & Scientific Advisor Comp: $177.66kDr. Lawrence Corey M.D. (Age 76)Co-Founder & Scientific Advisor Dr. Louis J. Picker M.D.Co-Founder & Scientific AdvisorDr. Jennifer Eileen Towne Ph.D.Executive VP & Chief Scientific OfficerMs. Heather Rowe ArmstrongVice President of Investor RelationsMs. Vanina De Verneuil J.D.Executive VP, General Counsel & Corporate SecretaryMore ExecutivesKey CompetitorsReplimune GroupNASDAQ:REPLFate TherapeuticsNASDAQ:FATEAllogene TherapeuticsNASDAQ:ALLObluebird bioNASDAQ:BLUEChina Biologic ProductsNASDAQ:CBPOView All CompetitorsInsiders & InstitutionsSaira RamasastrySold 4,000 sharesTotal: $43,800.00 ($10.95/share)Tidal Investments LLCBought 34,750 shares on 5/17/2024Ownership: 0.026%Comerica BankSold 2,990 shares on 5/17/2024Ownership: 0.024%Jacobs Levy Equity Management Inc.Bought 16,615 shares on 5/16/2024Ownership: 0.228%California State Teachers Retirement SystemSold 4,393 shares on 5/16/2024Ownership: 0.068%View All Insider TransactionsView All Institutional Transactions VIR Stock Analysis - Frequently Asked Questions Should I buy or sell Vir Biotechnology stock right now? 7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Vir Biotechnology in the last twelve months. There are currently 3 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" VIR shares. View VIR analyst ratings or view top-rated stocks. What is Vir Biotechnology's stock price target for 2024? 7 Wall Street analysts have issued 12-month price objectives for Vir Biotechnology's stock. Their VIR share price targets range from $12.00 to $110.00. On average, they anticipate the company's stock price to reach $34.14 in the next twelve months. This suggests a possible upside of 229.6% from the stock's current price. View analysts price targets for VIR or view top-rated stocks among Wall Street analysts. How have VIR shares performed in 2024? Vir Biotechnology's stock was trading at $10.06 at the beginning of 2024. Since then, VIR stock has increased by 3.0% and is now trading at $10.36. View the best growth stocks for 2024 here. When is Vir Biotechnology's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, August 1st 2024. View our VIR earnings forecast. How were Vir Biotechnology's earnings last quarter? Vir Biotechnology, Inc. (NASDAQ:VIR) issued its earnings results on Thursday, May, 2nd. The company reported ($0.48) earnings per share for the quarter, beating the consensus estimate of ($0.99) by $0.51. The firm earned $56.38 million during the quarter, compared to the consensus estimate of $11.71 million. Vir Biotechnology had a negative trailing twelve-month return on equity of 32.58% and a negative net margin of 677.69%. Vir Biotechnology's revenue was down 10.5% on a year-over-year basis. During the same quarter last year, the company earned ($1.06) EPS. What ETFs hold Vir Biotechnology's stock? ETFs with the largest weight of Vir Biotechnology (NASDAQ:VIR) stock in their portfolio include Amplify Treatments, Testing and Advancements ETF (GERM), Global X Genomics & Biotechnology ETF (GNOM), iShares Genomics Immunology and Healthcare ETF (IDNA), Virtus LifeSci Biotech Clinical Trials ETF (BBC), ALPS Medical Breakthroughs ETF (SBIO), Invesco S&P SmallCap Health Care ETF (PSCH) and Hypatia Women CEO ETF (WCEO).SPDR S&P 600 Small Cap ETF (SLY). What is George Scangos' approval rating as Vir Biotechnology's CEO? 7 employees have rated Vir Biotechnology Chief Executive Officer George Scangos on Glassdoor.com. George Scangos has an approval rating of 85% among the company's employees. When did Vir Biotechnology IPO? Vir Biotechnology (VIR) raised $149 million in an initial public offering (IPO) on Friday, October 11th 2019. The company issued 7,100,000 shares at a price of $20.00-$22.00 per share. Goldman Sachs, J.P. Morgan, Cowen and Barclays served as the underwriters for the IPO. Who are Vir Biotechnology's major shareholders? Vir Biotechnology's stock is owned by many different retail and institutional investors. Top institutional investors include Vanguard Group Inc. (9.20%), Baillie Gifford & Co. (2.93%), Principal Financial Group Inc. (0.34%), Empowered Funds LLC (0.34%), Jacobs Levy Equity Management Inc. (0.23%) and Nordea Investment Management AB (0.18%). Insiders that own company stock include Ann M Hanly, Backer Marianne De, Charles Elliott Sigal, Endurance (Cayman) Ltd Svf, George A Scangos, Herbert Virgin, Howard Horn, Janet Napolitano, Johanna Friedl-Naderer, Medpace Investors, Llc, Phillip Pang, Robert J More, Robert J More, Saira Ramasastry, Steven J Rice, Sung Lee, Vicki L Sato and Vicki L Sato. View institutional ownership trends. How do I buy shares of Vir Biotechnology? Shares of VIR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:VIR) was last updated on 6/13/2024 by MarketBeat.com Staff From Our PartnersThe #1 Crypto That You Don’t Own… YetThere’s all kinds of “signals” to follow when investing in cryptos. But there’s one signal you should pay a...Crypto 101 Media | SponsoredBiden’s Tax Plan Could Destroy Your Retirement Savings!Leading economists are issuing stark warnings: The anticipated capital gains tax increase under President B...GoldenCrest Metals | SponsoredLike Investing in Big Tech in the Early 2000s?More than a decade after the first Bitcoin was mined, people are finally realizing something very important......Manward Press | SponsoredEstee Lauder, MAC, and other beauty brands are raving about this emerging NYSE AI companyA Little-known NYSE Company is Empowering the Beauty Industry with Innovative AI and AR Tools.Financial Markets Daily | SponsoredTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...Daily Market Alerts | SponsoredTop 5 AI Stocks to Buy for 2024The electric vehicle boom is accelerating – and fast.Market Moving Trends | SponsoredHurry! Buy this stock before the Robinhood traders do!Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | SponsoredAI's Next Magnificent SevenThe Original Magnificent Seven Produced 16,894% Average Returns Over 20 Years.The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vir Biotechnology, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Vir Biotechnology With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.